The Centers for Medicare and Medicaid Services (CMS) identified 15 drugs it has selected for price negotiations with drug ...

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

Expanding volumes of data point to mechanisms beyond weight loss and blood sugar control that contribute to cardiovascular ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Wegovy's success, coupled with the recognition ... has since gained approvals for obesity and other metabolic indications. Currently, semaglutide is approved for type 2 diabetes, obesity, and ...

and is in development for four additional indications, including chronic kidney disease. Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over ...

Canadian public and private insurers have balked at covering certain medication for weight-loss, but that might change as the ...

Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could ...

Ongoing studies are exploring additional indications, such as reducing cardiovascular ... areas to broaden Zepbound's market potential. Wegovy has been a game-changer in the obesity sector ...

There are now seven approved GLP-1RAs. Commercially, the most successful one so far is semaglutide, sold under the brand name Wegovy or Ozempic depending on the indication.